Nabriva Therapeutics

Ahead of FDA decisions on one antibiotic, Nabriva plans resubmission of another
Ahead of FDA decisions on one antibiotic, Nabriva plans resubmission of another
BioCentury
Nabriva Therapeutics
antibiotics
lefmulin
Flag link:
Four New Drugs are Around the Corner. Here’s What You Need to Know.
Four New Drugs are Around the Corner. Here’s What You Need to Know.
Xconomy
FDA
drug approvals
AbbVie
Upadacitinib
Exondys 51
Sarepta Therapeutics
Nabriva Therapeutics
lefamulin
Roche
Rozlytrek
Flag link:
FDA Action Alert: Regeneron, Sanofi, Celgene
FDA Action Alert: Regeneron, Sanofi, Celgene
BioSpace
FDA
drug approvals
Acer Therapeutics
Edsivo
Regeneron
Sanofi
Dupixent
Celgene
Revlimid
Alexion
Soliris
Dova Pharmaceuticals
Doptelet
Nabriva Therapeutics
Contepo
Retrophin
Thiola
Flag link:
Nabriva's Antibiotic Contempo Turned Down by FDA Over Manufacturing Issues
Nabriva's Antibiotic Contempo Turned Down by FDA Over Manufacturing Issues
BioSpace
Nabriva Therapeutics
Contempo
antibiotics
FDA
drug manufacturing
Flag link:
Nabriva shares leap higher on antibiotic trial success
Nabriva shares leap higher on antibiotic trial success
BioPharma Dive
Nabriva Therapeutics
antibiotics
clinical trials
lefamulin
Flag link:
Antibiotics biotech Nabriva shoots for a $92M IPO
Antibiotics biotech Nabriva shoots for a $92M IPO
Fierce Biotech
Nabriva Therapeutics
IPOs
antibiotics
lefamulin
Flag link:
Forest Laboratories and Nabriva sign development agreement for anti-bacterial drug
Forest Laboratories and Nabriva sign development agreement for anti-bacterial drug
Proactive Investors
Nabriva Therapeutics
Forest Labs
BC-3781
antibiotics
Flag link:
Forest Laboratories and Nabriva Therapeutics Sign Agreement
Forest Laboratories and Nabriva Therapeutics Sign Agreement
Yahoo
Forest Labs
Nabriva Therapeutics
BC-3781
M&A
Flag link: